Status:
COMPLETED
Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study
Lead Sponsor:
US Department of Veterans Affairs
Collaborating Sponsors:
Kessler Foundation
Conditions:
Spinal Cord Injury
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Insulin-like growth factor I (IGF-I) is used as a measure of the body's ability to produce growth hormone. Growth hormone is important for muscle tissue as well as many other tissues in the body. Grow...
Eligibility Criteria
Inclusion
- Patients with chronic SCI (injury greater than 6 months) who have been screened and found to have depressed plasma IGF-1 levels and who are not taking baclofen.
Exclusion
- Acute illness of any etiology,
- Patients with chronic renal, liver, lung, or cardiac disease,
- Patients receiving any of the following medications: narcotics, or L-DOPA, and
- Alcoholics.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00871455
Start Date
April 1 2003
End Date
December 1 2011
Last Update
April 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center, Bronx
The Bronx, New York, United States, 10468